ReviewInternational journal of clinical oncology2019
Immune check-point in endometrial cancer.
Review in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.Journal of the American Heart Association · 2024Pooled it
- Differential expression of estrogen and progesterone receptors before and after surgery in endometrial cancer and analysis of recurrence prediction model.World journal of surgical oncology · 2026Article
- Habitat model based on transvaginal ultrasound images for non-invasive prediction of lymphatic vessel interstitial infiltration in endometrial cancer.World journal of surgical oncology · 2026Article
- Treatment strategies for advanced and recurrent endometrial cancer using immune checkpoint inhibitors.International journal of clinical oncology · 2025Review
- Surgery for patients with endometrioid-type endometrial cancer: is lymphadenectomy above the inferior mesenteric artery necessary?World journal of surgical oncology · 2024Article
- Association of CYP7B1 expression with the prognosis of endometrial cancer: a retrospective study.World journal of surgical oncology · 2024Article
- POLE -related gene signature predicts prognosis, immune feature, and drug therapy in human endometrioid carcinoma.Heliyon · 2024Article
- Mechanism of regulation of KIF23 on endometrial cancer cell growth and apoptosis.Discover oncology · 2024Article
- Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma.Translational cancer research · 2023Article
- Synaptotagmin-like protein 1 is a potential diagnostic and prognostic biomarker in endometrial cancer based on bioinformatics and experiments.Journal of ovarian research · 2023Article
- Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.Scientific reports · 2022Article
- TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.World journal of surgical oncology · 2022Article
- Crosstalk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma.Cancers · 2022Article
- Identification of molecular subtypes premised on the characteristics of immune infiltration of endometrial cancer.Annals of translational medicine · 2022Article
- Identification of m6A modification patterns and development of m6A-hypoxia prognostic signature to characterize tumor microenvironment in triple-negative breast cancer.Frontiers in immunology · 2022Article
- Single cell sequencing analysis and transcriptome analysis constructed the liquid-liquid phase separation(LLPS)-related prognostic model for endometrial cancer.Frontiers in oncology · 2022Article
- Integrated Bioinformatics Analysis of Serine Racemase as an Independent Prognostic Biomarker in Endometrial Cancer.Frontiers in genetics · 2022Article
- Molecular subtypes, clinical significance, and tumor immune landscape of angiogenesis-related genes in ovarian cancer.Frontiers in oncology · 2022Article
- The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling.Bioengineered · 2021Article
- The Hallmarks of Flavonoids in Cancer.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial cancer (EC) is one of the most frequent tumors in women. Despite recent advances in treatment approaches, the prognosis in advanced, recurrent, or metastatic disease remains poor. The aim was to provide the clinician with an update, the current status, and the new developments in the management of EC. Based on the new EC molecular classification, we focused on the impact of immune check-point inhibitors.
methodsPivotal trials, published literature, and conference proceedings were reviewed. PubMed and Scopus databases were searched to select English-language articles.
resultsImmune check-point inhibitors are the subject of ongoing studies and their benefit seems to be related to microsatellite instability (MSI) status.
conclusionsImmune check-point inhibitors should be considered a promising treatment option to better personalize therapeutic strategies in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.